#8317. Acute and long-term effects of saxagliptin on a set of cardiovascular targets measured at fasting and post-prandially in obese patients with impaired glucose tolerance: A placebo-controlled study

October 2026publication date
Proposal available till 08-06-2025
4 total number of authors per manuscript0 $

The title of the journal is available only for the authors who have already paid for
Journal’s subject area:
Cardiology and Cardiovascular Medicine;
Medicine (miscellaneous);
Endocrinology, Diabetes and Metabolism;
Nutrition and Dietetics;
Places in the authors’ list:
place 1place 2place 3place 4
FreeFreeFreeFree
2350 $1200 $1050 $900 $
Contract №8317.1 Contract №8317.2 Contract №8317.3 Contract №8317.4
1 place - free (for sale)
2 place - free (for sale)
3 place - free (for sale)
4 place - free (for sale)

Abstract:
Background and aims: Studies of dipeptidyl peptidase inhibitors (DPP4is) report heterogeneous effects on cardiovascular targets in type 2 diabetes. This study aimed to investigate, in patients with impaired glucose tolerance (IGT), whether saxagliptin, a DPP4i, had beneficial cardiovascular effects at fasting and during the post-prandial state. Methods and results: In this randomized, placebo-controlled, double-blind, single-center pilot exploratory study, we included obese individuals with IGT.
Keywords:
Arterial stiffness; Autonomic nervous system; Dipeptidyl peptidase inhibitor; Endothelium; Impaired glucose tolerance; Microcirculation; Post-prandial; Saxagliptin

Contacts :
0